AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Clinical trial NCT06464068 · RECRUITING
Trial details
- NCT number
- NCT06464068
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-16
- Primary completion
- 2028-01-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.